<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Features of selected antimicrobials used for outpatient parenteral antibiotic therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Features of selected antimicrobials used for outpatient parenteral antibiotic therapy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Features of selected antimicrobials used for outpatient parenteral antibiotic therapy</div><div class="cntnt"><table cellspacing="0"><colgroup span="11" width="9%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Anti-infective</td> <td class="subtitle1" rowspan="2">Oral bioavailability (percent)*</td> <td class="subtitle1" rowspan="2">Doses per day<sup>¶</sup></td> <td class="subtitle1" rowspan="2">Infusion time</td> <td class="subtitle1" rowspan="2">Delivery device<sup>Δ</sup></td> <td class="subtitle1" colspan="3">Monitoring frequency<sup>◊</sup></td> <td class="subtitle1" rowspan="2">Most common potentially serious ADRs</td> <td class="subtitle1" rowspan="2">Torsades de Pointes risk<sup>§</sup></td> <td class="subtitle1" rowspan="2">Other comments</td> </tr> <tr> <td class="subtitle2">CBC-diff</td> <td class="subtitle2">BMP: including K, Cr, BUN</td> <td class="subtitle2">Liver profile: ALT, AST, ALK, Tbil</td> </tr> <tr class="divider_bottom"> <td>Amikacin</td> <td>NA</td> <td>1 to 3</td> <td>30 to 60 minutes depending on dose</td> <td>Grav, Elas</td> <td>Once weekly</td> <td>Twice weekly</td> <td>Not required routinely</td> <td>Nephrotoxicity; ototoxicity</td> <td> </td> <td>Refer to aminoglycoside monitoring<sup>¥</sup></td> </tr> <tr class="divider_bottom"> <td>Ampicillin</td> <td>50</td> <td>4 to 6</td> <td>3 to 5 minutes push or 10 to 15 minutes infusion</td> <td>Grav, EID, IVP</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>Stable once reconstituted for only 3 days; refer to stability footnote<sup>‡</sup></td> </tr> <tr class="divider_bottom"> <td>Ampicillin-sulbactam</td> <td>NA</td> <td>3 to 4</td> <td>10 to 15 minutes push or 15 to 30 minutes infusion</td> <td>Grav, EID, Elas, IVP</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>Stable once reconstituted for only 3 days; refer to stability footnote<sup>‡</sup></td> </tr> <tr class="divider_bottom"> <td>Azithromycin</td> <td>28 to 52</td> <td>1</td> <td>60 minutes</td> <td>Grav</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Not required routinely</td> <td> </td> <td>Known</td> <td>Consider change to po</td> </tr> <tr class="divider_bottom"> <td>Aztreonam</td> <td>NA</td> <td>2 to 4</td> <td>3 to 5 minutes push or 20 to 60 minutes infusion</td> <td>Grav, EID, Elas, IVP</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td> </td> <td> </td> <td>Rare cross-allergenicity with other beta-lactams</td> </tr> <tr class="divider_bottom"> <td>Cefazolin</td> <td>NA</td> <td>3 to 4</td> <td>3 to 5 minutes push or 30 to 60 minutes infusion</td> <td>Grav, Elas, IVP</td> <td>Once weekly</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>Dialysis-only dosing possible</td> </tr> <tr class="divider_bottom"> <td>Cefepime</td> <td>NA</td> <td>2 to 3</td> <td>5 minutes push or 30 minutes infusion</td> <td>Grav, Elas, IVP</td> <td>Once weekly</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>Dialysis-only dosing possible</td> </tr> <tr class="divider_bottom"> <td>Cefoxitin</td> <td>NA</td> <td>3 to 4</td> <td>3 to 5 minutes push or 20 to 30 minutes infusion</td> <td>Grav, Elas, IVP</td> <td>Once weekly</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td> </td> </tr> <tr class="divider_bottom"> <td>Ceftaroline</td> <td>NA</td> <td>2 to 3</td> <td>5 minutes push or 5 to 60 minutes</td> <td>Grav, IVP</td> <td>Once weekly</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td> </td> </tr> <tr class="divider_bottom"> <td>Ceftazidime</td> <td>NA</td> <td>3</td> <td>3 to 5 minutes push or 15 to 30 minutes infusion</td> <td>Grav, Elas, IVP</td> <td>Once weekly</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Hypersensitivity including anaphylaxis</td> <td>NA</td> <td>Dialysis-only dosing possible</td> </tr> <tr class="divider_bottom"> <td>Ceftazidime-avibactam</td> <td>NA</td> <td>3</td> <td>120 minutes</td> <td>Grav, EID</td> <td>Once weekly</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>…</td> </tr> <tr class="divider_bottom"> <td>Ceftolozane-tazobactam</td> <td>NA</td> <td>3</td> <td>60 minutes</td> <td>Grav, EID</td> <td>Once weekly</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>…</td> </tr> <tr class="divider_bottom"> <td>Ceftriaxone</td> <td>NA</td> <td>1 to 2</td> <td>1 to 4 minutes push or 30 minutes infusion</td> <td>Grav, Elas, IVP</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>Refer to monitoring footnote<sup>◊</sup></td> </tr> <tr class="divider_bottom"> <td>Ciprofloxacin</td> <td>50 to 85</td> <td>2 to 3</td> <td>60 minutes</td> <td>Grav, Elas</td> <td>Not required routinely</td> <td>Not required routinely</td> <td>Not required routinely</td> <td>Tendonitis/tendon rupture; peripheral neuropathy</td> <td>Known</td> <td>Consider change to po; refer to monitoring footnote<sup>◊</sup></td> </tr> <tr class="divider_bottom"> <td>Clindamycin</td> <td>90</td> <td>3 to 4</td> <td>10 to 60 minutes (not to exceed 30 mg/minute)</td> <td>Grav, Elas</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td> </td> <td> </td> <td>Consider change to po; refer to monitoring footnote<sup>¥</sup></td> </tr> <tr class="divider_bottom"> <td>Colistin</td> <td>NA</td> <td>2 to 4</td> <td>3 to 5 minutes IVP; 30 minutes for infusion</td> <td>Grav, IVP</td> <td>Once weekly</td> <td>Twice weekly</td> <td>Not required routinely</td> <td>Nephro- and neurotoxicity</td> <td> </td> <td>Inhaled colistin may be an option for respiratory tract infections</td> </tr> <tr class="divider_bottom"> <td>Daptomycin</td> <td>NA</td> <td>1</td> <td>2 minutes push or 30 minutes infusion</td> <td>Grav, Elas, IVP</td> <td>Once weekly</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Myopathy; rhabdomyolysis</td> <td> </td> <td>Baseline and weekly CK, discontinue if symptomatic and CK &gt;1000 units/L (~5× ULN) or asymptomatic and CK &gt;2000 units/L (~10 minutes ULN); dialysis-only dosing possible</td> </tr> <tr class="divider_bottom"> <td>Dalbavancin</td> <td>NA</td> <td>Once per week</td> <td>30 minutes</td> <td>Grav</td> <td>Not required routinely</td> <td>Not required routinely</td> <td>Not required routinely</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>Vancomycin flushing reaction more likely if infusion &lt;30 minutes; monitoring requirements unknown for treatment duration greater than 2 weeks</td> </tr> <tr class="divider_bottom"> <td>Ertapenem</td> <td>NA</td> <td>1</td> <td>30 minutes</td> <td>Grav, Elas</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hypersensitivity including anaphylaxis</td> <td>NA</td> <td>Refer to stability footnote<sup>‡</sup></td> </tr> <tr class="divider_bottom"> <td>Gentamicin</td> <td>NA</td> <td>1 to 3</td> <td>30 to 120 minutes depending on dose</td> <td>Grav, EID, Elas</td> <td>Once weekly</td> <td>Twice weekly</td> <td>Not required routinely</td> <td>Nephrotoxicity; ototoxicity</td> <td> </td> <td>Refer to aminoglycoside monitoring<sup>¥</sup></td> </tr> <tr class="divider_bottom"> <td>Imipenem</td> <td>NA</td> <td>3 to 4</td> <td>20 to 60 minutes depending on dose</td> <td>Grav</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hypersensitivity including anaphylaxis; seizures</td> <td> </td> <td>Refer to stability footnote<sup>‡</sup></td> </tr> <tr class="divider_bottom"> <td>Levofloxacin</td> <td>90</td> <td>1</td> <td>60 to 90 minutes depending on dose</td> <td>Grav</td> <td>Not required routinely</td> <td>Not required routinely</td> <td>Not required routinely</td> <td>Tendonitis/tendon rupture; cardiac arrhythmias; peripheral neuropathy</td> <td>Known</td> <td>Consider change to po; refer to monitoring footnote;<sup>◊</sup> dialysis-only dosing possible</td> </tr> <tr class="divider_bottom"> <td>Linezolid</td> <td>100</td> <td>2</td> <td>30 to 120 minutes</td> <td>Grav, EID</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Once weekly</td> <td>Thrombocytopenia; leukopenia; anemia; peripheral neuropathy; optic neuritis</td> <td> </td> <td>Consider change to po; monitor for neuropathy, optic neuritis in prolonged use; refer to monitoring footnote;<sup>◊</sup> potential for drug interactions</td> </tr> <tr class="divider_bottom"> <td>Meropenem</td> <td>NA</td> <td>3 to 4</td> <td>30 minutes</td> <td>Grav, Elas</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>Dialysis-only dosing possible; refer to stability footnote<sup>‡</sup></td> </tr> <tr class="divider_bottom"> <td>Metronidazole</td> <td>100</td> <td>2 to 4</td> <td>30 to 60 minutes</td> <td>Grav, EID, Elas</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Not required routinely</td> <td>Peripheral neuropathy</td> <td>Conditional</td> <td>Consider change to po</td> </tr> <tr class="divider_bottom"> <td>Nafcillin</td> <td>NA</td> <td>4 to 6</td> <td>30 to 60 minutes</td> <td>Grav, EID</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>Central line commonly used because of concern for phlebitis risk</td> </tr> <tr class="divider_bottom"> <td>Oritavancin</td> <td>NA</td> <td>Once</td> <td>180 minutes</td> <td>Grav</td> <td>Not required routinely</td> <td>Not required routinely</td> <td>Not required routinely</td> <td>Hypersensitivity including anaphylaxis; infusion related</td> <td> </td> <td>Vancomycin flushing reaction more likely if infusion &lt;60 minutes; monitoring requirements unknown for treatment duration greater than a single dose</td> </tr> <tr class="divider_bottom"> <td>Oxacillin</td> <td>NA</td> <td>4 to 6</td> <td>10 to 30 minutes</td> <td>Grav, Elas</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hypersensitivity including anaphylaxis; hepatotoxicity</td> <td> </td> <td>Central line commonly used because of concern for phlebitis risk</td> </tr> <tr class="divider_bottom"> <td>Penicillin G</td> <td>25 to 73</td> <td>4 to 6</td> <td>15 to 30 minutes</td> <td>Grav, EID</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td>Oral penicillin V K is not a substitute for IV treatment of most clinical conditions requiring IV penicillin, eg, syphilis</td> </tr> <tr class="divider_bottom"> <td>Piperacillin-tazobactam</td> <td>NA</td> <td>3 to 4</td> <td>30 to 240 minutes (extended infusion)</td> <td>Grav, EID</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hypersensitivity including anaphylaxis</td> <td> </td> <td> </td> </tr> <tr class="divider_bottom"> <td>Polymyxin B</td> <td>NA</td> <td>1</td> <td>60 to 90 minutes</td> <td>Grav</td> <td>Once weekly</td> <td>Twice weekly</td> <td>Not required routinely</td> <td>Nephro- and neurotoxicity</td> <td> </td> <td>Monitor for nephrotoxicity, neurotoxicity</td> </tr> <tr class="divider_bottom"> <td>Rifampin</td> <td>70 to 90</td> <td>1 to 3</td> <td>30 minutes</td> <td>Grav</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hepatitis; hypersensitivity</td> <td>NA</td> <td>Potential for drug–drug interactions; consider change to po</td> </tr> <tr class="divider_bottom"> <td>Tedizolid</td> <td>91</td> <td>1</td> <td>60 minutes</td> <td>Grav</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Once weekly</td> <td>Thrombocytopenia; leukopenia; anemia; peripheral neuropathy; optic neuritis</td> <td> </td> <td>Consider change to po; monitor for neuropathy, optic neuritis in prolonged use; potential for drug interactions; refer to monitoring footnote<sup>◊</sup></td> </tr> <tr class="divider_bottom"> <td>Telavancin</td> <td>NA</td> <td>1</td> <td>60 minutes</td> <td>Grav</td> <td>Once weekly</td> <td>Twice weekly</td> <td>Not required routinely</td> <td>Nephrotoxicity; hypersensitivity including anaphylaxis; infusion-related prolongation of QTc</td> <td>Possible</td> <td>High rate of renal injury in patients aged &gt;65 years, with preexisting renal impairment or other nephrotoxins; vancomycin flushing reaction more likely if infusion &lt;60 minutes</td> </tr> <tr class="divider_bottom"> <td>Tigecycline</td> <td>NA</td> <td>2</td> <td>30 to 60 minutes</td> <td>Grav</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Nausea/vomiting</td> <td> </td> <td> </td> </tr> <tr class="divider_bottom"> <td>Tobramycin</td> <td>NA</td> <td>1 to 3</td> <td>30 to 120 minutes depending on dose</td> <td>Grav, EID, Elas</td> <td>Once weekly</td> <td>Twice weekly</td> <td>Not required routinely</td> <td>Nephrotoxicity; ototoxicity</td> <td> </td> <td>Refer to aminoglycoside monitoring<sup>¥</sup></td> </tr> <tr class="divider_bottom"> <td>Trimethoprim/sulfamethoxazole</td> <td>85</td> <td>2 to 4</td> <td>60 to 90 minutes</td> <td>Grav</td> <td>Once weekly</td> <td>Once weekly</td> <td>Once weekly</td> <td>Hyperkalemia; rash; nephrotoxicity; Stevens Johnson syndrome</td> <td>Special</td> <td>Consider change to po; potential for drug–drug interactions; high fluid requirement; spurious increase in serum creatinine</td> </tr> <tr> <td>Vancomycin</td> <td>NA</td> <td>1 to 2</td> <td>60 to 120 minutes depending on dose</td> <td>Grav, EID, Elas</td> <td>Once weekly</td> <td>Once weekly</td> <td>Not required routinely</td> <td>Nephrotoxicity; infusion-related reactions</td> <td> </td> <td>Dialysis-only dosing possible; vancomycin trough levels or area under the curve/minimum inhibitory concentration weekly and with dose changes; vancomycin flushing reaction more likely if infusion &lt;60 minutes</td> </tr> </tbody></table></div><div class="graphic_lgnd">Use of the information presented in this table should be tailored to individual patient circumstances.</div><div class="graphic_footnotes">CBC: complete blood cell count;

	BMP: basic metabolic profile;  

	K: potassium; 

	Cr: creatinine;  

	BUN: blood urea nitrogen;  

	ALT: alanine transaminase;

	AST: aspartate transaminase;

	ALK: alkaline phosphatase; 

	Tbil: total bilirubin;	

	ADR: adverse drug reaction;

	NA: not applicable/no oral formulation; 

	Grav: gravity; 

	Elas: elastomeric;   

	EID: electronic infusion device;

	IVP: intravenous push;  

	po: by mouth;

	CK: creatine kinase; 

	ULN: upper limit of normal; 

	IV: intravenous; 

	QTc: corrected QT-interval; 

	LFT: liver function tests.<br/>

	* Bioavailability: changing to oral medications when possible is part of good antimicrobial stewardship. Clinicians should consider the full clinical situation, including the appropriateness of oral antimicrobials for the condition being treated. Potential for interaction with foods and other medications as well as concomitant illnesses and the potential for impaired gut absorption must also be considered.<br/>

	¶ Doses per day: assumes normal renal and hepatic function. More than 2 to 3 doses per day may be impractical for pediatric outpatient parenteral antimicrobial therapy (OPAT) that requires adult infusion assistance for every dose. Dosing more frequently than once daily is typically not practical for patients who receive care in infusion centers.<br/>

	Δ Devices: very limited published information on the use of these devices in OPAT. Individual infusion pharmacies have variable policies and device availability. Not all drugs are compatible with all delivery options. EIDs can be programmed to automatically deliver multiple doses per day but they require that the patient be connected to a small device virtually continuously and are not covered by all insurance carriers. Elas are very simple to use but also are not covered by all insurance carriers. Gravity delivery (infusion without a pump, using a roller clamp) is less expensive but also less convenient due to longer infusion times and complexity for patients to learn. Depending upon care setting, use of a traditional infusion pump may be selected in lieu of gravity for rate control. IVP is very convenient because of rapid infusion time.<br/>
<span class="lozenge">◊</span> These are recommendations based on frequency and seriousness of reported adverse events. The monitoring plan for an individual patient may be different based on the comorbid conditions and anticipated duration of OPAT. For instance, for shorter courses of linezolid, ceftriaxone, or clindamycin, it may not be necessary to monitor LFTs and/or renal function. Alternatively, for longer courses of fluoroquinolones, weekly lab monitoring may be appropriate. For patients with normal baseline labs, less intense monitoring may be appropriate.<br/>

	§ Risk of Torsades de Pointes (TdP): known, known to prolong QTc interval and cause TdP even when taken as recommended; possible, can cause QTc prolongation but not known to cause TdP when taken as recommended; conditional, associated with TdP but only under certain conditions (ie, excessive dose, with hypokalemia, with other interacting drugs) or by creating conditions that induce TdP (inhibiting metabolism of QTc prolonging drugs); special, high risk of TdP in patients with congenital long QT syndromes due to other actions. Source for TdP risk<sup>[1]</sup>.<br/>

	¥ Aminoglycoside monitoring: monitor concentrations minimum weekly. Goal aminoglycoside trough values differ according to the drug, infection, and dosing strategy.<br/>

	‡ For medications with limited stability, home delivery more frequently than once weekly will be required. Some drugs may be reconstituted in the home using a use-activated container, if available.</div><div class="graphic_reference">Reference: 

<ol>
<li>Woosley RL, Heise CW, Gallo T, et al. QTdrugs List. Oro Valley, AZ: AZCERT, Inc. Available at: <a href="https://www.crediblemeds.org" target="_blank">https://www.crediblemeds.org</a>.</li></ol>
<p>Adapted from: Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. Clin Infect Dis 2019;68(1):e1-e35. By permission of Oxford University press on behalf of the Infectious Diseases Society of America. Copyright © 2018. Adapted from: Shah A, Norris A. Handbook of Outpatient Parenteral Antimicrobial Therapy For Infectious Diseases, 3rd edition.<br/>Disclaimer: OUP and the IDSA. are not responsible or in any way liable for the accuracy of the modified table. The Licensee is solely responsible for the modified table in this publication.</p></div><div id="graphicVersion">Graphic 121957 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
